# Anthem Biosciences (NSE: ANTHEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ANTHEM · Pivot · prices to 22 Oct 2026

Anthem Biosciences (NSE: ANTHEM) closed at ₹802.40 on 22 Oct 2026, down 0.52% on the day. With a market capitalisation of ₹45,206 Cr, it ranks 209th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

At its last close the stock traded at 76.6× trailing earnings, against a return on equity of 19.5% in FY26. Over the past year the share price has risen 3.0%. Its 52-week range is ₹579.15 (2 Feb 2026) to ₹977.55 (9 Sep 2026); the last close is 17.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹418 Cr (−22.6% year on year) and net profit ₹120 Cr (−11.7%), on a consolidated basis. Promoters held 71.42% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹802.40 |
| Market cap | ₹45,206 Cr |
| P/E (trailing) | 76.6 |
| ROE | 19.5% (FY26) |
| ROCE | 27.6% (FY26) |
| Debt to equity | 0.02 |
| 52-week high | ₹977.55 (9 Sep 2026) |
| 52-week low | ₹579.15 (2 Feb 2026) |
| 1-year return | +3.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹418 Cr | −22.6% | ₹120 Cr | −11.7% | ₹2.13 |
| Q4 FY26 | ₹611 Cr | +26.4% | ₹190 Cr | +129.7% | ₹3.38 |
| Q3 FY26 | ₹423 Cr | −15.0% | ₹93 Cr | −25.3% | ₹1.65 |
| Q2 FY26 | ₹550 Cr | +4.8% | ₹173 Cr | +7.1% | ₹3.09 |
| Q1 FY26 | ₹540 Cr | +59.5% | ₹136 Cr | +64.8% | ₹2.43 |
| Q4 FY25 | ₹483 Cr | — | ₹83 Cr | — | ₹1.48 |
| Q3 FY25 | ₹498 Cr | — | ₹124 Cr | — | ₹2.22 |
| Q2 FY25 | ₹525 Cr | — | ₹162 Cr | — | ₹2.90 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,845 Cr | ₹451 Cr |
| FY24 | ₹1,419 Cr | ₹367 Cr |
| FY23 | ₹1,057 Cr | ₹385 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 71.42%
- Foreign institutions: 2.58%
- Domestic institutions: 13.48%
- Non-institutions: 12.53%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹54,244 Cr | 117.6 | — |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹54,069 Cr | 34.8 | — |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹49,038 Cr | 43 | — |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,910.60 | ₹48,013 Cr | 46.7 | — |
| [GlaxoSmithKline Pharmaceuticals](https://app.pivotnow.in/stock/GLAXO) | ₹2,455.20 | ₹41,593 Cr | 40.1 | — |
| [Ajanta Pharma](https://app.pivotnow.in/stock/AJANTPHARM) | ₹3,260.00 | ₹40,729 Cr | 38.6 | — |

## Questions and answers

### What is the share price of Anthem Biosciences today?

Anthem Biosciences (NSE: ANTHEM) last closed at ₹802.40 on 22 Oct 2026. Its 52-week high is ₹977.55 and its 52-week low is ₹579.15.

### What is the market cap of Anthem Biosciences?

Anthem Biosciences' market capitalisation is ₹45,206 Cr (₹45,206 Cr) at the 22 Oct 2026 close, ranking 209th among the NSE companies Pivot tracks.

### What is the P/E ratio of Anthem Biosciences?

Anthem Biosciences trades at a trailing P/E of 76.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.

### What is the ROE and ROCE of Anthem Biosciences?

Return on equity was 19.5% in FY26 and return on capital employed was 27.6% in FY26 (consolidated figures).

### Is Anthem Biosciences a debt-free company?

Anthem Biosciences is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.

### What were Anthem Biosciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Anthem Biosciences reported revenue of ₹418 Cr, −22.6% year on year, and net profit of ₹120 Cr, −11.7% year on year.

### How has Anthem Biosciences stock performed over the last year?

Anthem Biosciences' share price has risen 3.0% over the past year, +3.1% over three months and −12.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Anthem Biosciences?

As of 30 Jun 2026: promoters 71.42%, foreign institutions 2.58%, domestic institutions 13.48%, non-institutions 12.53%.

### Who are Anthem Biosciences' competitors?

The listed Pharma & Healthcare companies closest to Anthem Biosciences by market cap are Biocon, Abbott India, IPCA Laboratories, Gland Pharma, GlaxoSmithKline Pharmaceuticals and Ajanta Pharma.

### Is Anthem Biosciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Anthem Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANTHEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.